ArticleNature cancer2026

TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.

Qiwei Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.